Observational Study
Copyright ©The Author(s) 2017.
World J Hepatol. Apr 18, 2017; 9(11): 551-561
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.551
Figure 1
Figure 1 Outcomes of 223 patients inititating telaprevir- or boceprevir-based triple therapy. SVR: Sustained virological response.

  • Citation: Bichoupan K, Tandon N, Martel-Laferriere V, Patel NM, Sachs D, Ng M, Schonfeld EA, Pappas A, Crismale J, Stivala A, Khaitova V, Gardenier D, Linderman M, Olson W, Perumalswami PV, Schiano TD, Odin JA, Liu LU, Dieterich DT, Branch AD. Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol 2017; 9(11): 551-561
  • URL: https://www.wjgnet.com/1948-5182/full/v9/i11/551.htm
  • DOI: https://dx.doi.org/10.4254/wjh.v9.i11.551